Phase 3 N=1,633 A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
Migraine
Primary: Percentage of Participants That Are Pain Free 2 Hours Postdose During the First Attack — 25.8; 29.3; 8.4 percentage of participants — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=186 Dysport in Hallux Abducto Valgus (HAV) Phase IIa
Hallux Abducto Valgus
Primary: Least Square (LS) Mean Change From Baseline in the Daily Numeric Pain Rating Scale (NPRS) Score at Week 8 — -2.04; -1.71; -2.40 units on a scale — p=0.7669
Phase 2 N=23 A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
MPN (Myeloproliferative Neoplasms)
Primary: Change in Spleen Volume at Week 24 Compared to Baseline — 88.7; -207 cubic centimeter (cm^3)
Phase 3 N=296 Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
ADHD
Primary: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) — -13.2; -18.3; -16.7 units on a scale — p=0.0082
Phase 2 N=24 A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Overall Complete Remission Rate — 0; 0; 0; 0 Participants
Phase 1 N=60 Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) — 129; 207; 202; 290 ng/mL
N/A N=39 Exercise Training and Cognitive Function in Kidney Disease
Cognitive Function, Preclinical · Chronic Kidney Diseases · Older Adults
Primary: Composite Global Cognitive Function — .15; .02 Z-score
Phase 2 N=63 Phase 2 Herniorrhaphy Study for Opioid Elimination
Postoperative Pain
Primary: Percentage of Subjects Receiving no Opioid Rescue — 30; 27 Participants
Early Phase 1 N=28 Observational Study to Assess the Frequency of Lidocaine Ineffectiveness in Hard-to-treat ADHD
ADHD
Primary: Observational Study: Number of Participants With Lidocaine Ineffectiveness by Taste Test in Hard-to-treat ADHD — 1; 27 Participants
Phase 2 N=13 A Study of AK-01 (LY3295668) in Solid Tumors
Neoplasms · Neoplasm Metastasis · Triple Negative Breast Neoplasms
Primary: Phase 1: Maximum Tolerated Dose — 25 milligram (mg)
Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
Phase 3 N=259 The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis
Psoriasis
Primary: Area Under the Plasma Concentration Time Curve Over the Dosing Interval of Week 30 to 32 (AUCτ, 30-32) for Adalimumab in Plasma — 2040; 1980 microgram * hours / milliliter
N/A N=95 The Impact of the Attention Training Technique on Attention Control and High Worry
Excessive Worry
Primary: Breathing Focus Task -Negative Intrusions — 2.85; 2.55; 2.45; 2.26 score on a scale — p=.93
Phase 2 N=63 Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer
Colorectal Neoplasms
Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 — 0; 0; 2; 0 Participants
Phase 4 N=14 Anesthesia for Pain After Ankle Fracture Surgery
Chronic Pain · Ankle Fracture Surgery · Regional Anesthesia
Primary: Pain Score at 12 Months - Experimental Group vs. Control Group — 36.33; 44.00 units on a scale — p=0.1269